Ulcerative colitis (UC) is a relapsing inflammatory disorder of unconfirmed aetiology, variable severity and clinical course, characterised by progressive histological inflammation and with elevation of eicosanoids which have a known pathophysiological role in inflammation. Therapeutic interventions targetting eicosanoids (5-aminosalicylates (ASA)) are effective first line and adjunctive treatments in mild-moderate UC for achieving and sustaining clinical remission. However, the variable clinical response to 5-ASA and frequent deterioration in response to cyclo-oxygenase (COX) inhibitors, has prompted an in depth simultaneous evaluation of multiple lipid mediators (including eicosanoids) within the inflammatory milieu in UC. We hypothesised that severity of inflammation is associated with alteration of lipid mediators, in relapsing UC.
Study was case-control design. Mucosal lipid mediators were determined by LC-MS/MS lipidomics analysis on mucosal biopsies taken from patients attending outpatients with relapsing UC. Univariate and multivariate statistical analyses were used to investigate the association of mucosal lipid mediators, with the disease state and severity graded histologically.
Levels of PGE2, PGD2, TXB2, 5-HETE, 11-HETE, 12-HETE and 15-HETE are significantly elevated in inflamed mucosa and correlate with severity of inflammation, determined using validated histological scoring systems.
Our approach of capturing inflammatory mediator signature at different stages of UC by combining comprehensive lipidomics analysis and computational modelling could be used to classify and predict mild-moderate inflammation; however, predictive index is diminished in severe inflammation. This new technical approach could be developed to tailor drug treatments to patients with active UC, based on the mucosal lipid mediator profile.
Citation: Masoodi M, Pearl DS, Eiden M, Shute JK, Brown JF, Calder PC, et al. (2013) Altered Colonic Mucosal Polyunsaturated Fatty Acid (PUFA) Derived Lipid Mediators in Ulcerative Colitis: New Insight into Relationship with Disease Activity and Pathophysiology. PLoS ONE 8(10): e76532. https://doi.org/10.1371/journal.pone.0076532
Editor: Hiroyasu Nakano, Juntendo University School of Medicine, Japan
Received: May 17, 2013; Accepted: August 31, 2013; Published: October 18, 2013
Copyright: © 2013 Masoodi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Salary and research bursary provided by Portsmouth Hospitals National Health Service (NHS) Trust and University of Portsmouth, Portsmouth, United Kingdom and Medical Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Ulcerative colitis (UC) is a chronic, relapsing intestinal inflammatory disorder of the colonic mucosa, with variable distribution but limited to the distal bowel (distal colitis and proctitis) in 60% of cases . In distal colitis there is commonly a clear demarcation between inflamed and non-inflamed tissues that demonstrate contrasting patterns of immunomodulator release .
Despite advances in medical treatments, including biologics that target cytokine-led inflammatory responses for severe disease, long term control of UC is variable with available therapeutic interventions –, with 57% of all patients following a relapsing and remitting clinical course , . In mild to moderate relapsing disease only, a limited therapeutic repertoire is available to patients principally as oral or topical 5-aminosalicylic acid (5-ASA) and corticosteroids.
Mucosal inflammation in UC is characterised by an infiltrate of neutrophils, plasma cells and eosinophils, which correlate with disease severity and are predictors of disease relapse –. It is proposed that lipid inflammatory mediators, including eicosanoids, which are rapidly and locally formed and degraded in-situ, promote neutrophil chemotaxis , , a pivotal step in the inflammatory cascade. Furthermore, mucosal inflammation in UC responds to therapeutic interventions that target eicosanoid production such as 5-ASA , . However, the understanding of both the pathophysiology of UC and pharmacotherapeutic effects of 5-ASA is limited, which has inhibited the development of new therapeutic interventions.
Eicosanoids are a family of lipid mediators, derived from polyunsaturated fatty acids (PUFA) enzymatically and oxidatively . Previous studies have demonstrated up regulation of the eicosanoid biosynthetic enzymes cyclooxygenase (COX)-1, COX-2, and 5-lipoxygenase (LOX) in active UC  and elevation of both prostaglandin (PG)E2  and leukotriene (LT)B4  derived from the n-6 PUFA arachidonic acid (AA) in UC. Eicosanoids may also derive from the n-3 PUFA eicosapentaenoic acid (EPA); EPA-derived eicosanoids include PGE3 and LTB5. Frequently the mediators produced from AA and EPA differ in their inflammatory potency , . However, studies attempting to alter eicosanoid production through dietary modification of mucosal lipid profile in active UC have been disappointing, with only modest effects on relapse rates and corticosteroid requirement, despite sound experimental results in healthy volunteers , .
The aims of this study were to investigate the levels of PUFA-derived lipid mediators within inflamed colonic mucosa in mild to moderate UC, to determine their relationship to endoscopic and histological changes, to identify mediators that have not previously been considered possible contributors to the inflammatory cascade in UC, and, as a result, to identify potential targets for intervention. The investigation of patients with distal colitis enabled comparative assessment of endoscopically normal and inflamed tissues as a model, as previously described .
Materials and Methods
2.1. Subjects and Mucosal Biopsy
This was a case-control of UC patients identified during attendance at gastroenterology outpatients’ clinics at the Royal Haslar and St Mary’s Hospital, Portsmouth Hospitals NHS Trust between November 2008 and July 2009. The diagnosis of UC was based on endoscopic and histological investigation , . All recruited patients underwent a questionnaire-based assessment of their demographic characteristics, previous and presenting medical history, and UC history. Clinical disease activity was determined using the UCDAI score .
Patients with clinical evidence of active disease underwent unprepared flexible sigmoidoscopy examination as part of their routine clinical management. An endoscopy assessment was undertaken by two endoscopists blinded to the patient’s clinical presentation using a validated scoring tool to stratify patients into active or quiescent UC with photographic evidence obtained, and to identify demarcation of inflamed with apparently non-inflamed mucosa. Biopsies were taken according to a standard protocol, specifically developed to measure target analytes in adjacent areas of inflamed and non-inflamed mucosa in patients with active distal UC. Flexible sigmoidoscopy in patients with active distal UC to above visual demarcation of normal mucosa was followed by grab biopsy, obtained using flexible biopsy forceps, in endoscopically inflamed and non-inflamed areas. All mucosal biopsy samples were snap-frozen and stored in liquid nitrogen until use.
Exclusion criteria were age less than 16 or greater than 80 years; refusal to undergo endoscopic evaluation; diagnosis of colitis of alternative aetiology; concurrent use of non-steroidal anti-inflammatory medication; inability to provide consent.
The study was approved by the Isle of Wight, Portsmouth and South East Hampshire research ethics committee (project number 08/H0501/82). All subjects provided written informed consent.
2.2. Analysis of Lipid Mediators
2.2.1. Reagents and standards.
PGE2, PGD2, thromboxane (TX)B2, 6-keto-PGF1α, PGB2-d4, 13,14-dihydro-15-keto-PGE2, 9-hydroxy-10(E),12(Z)-octadecadienoic acid (9-HODE), 13-hydroxy-9(Z),11(E)-octadecadienoic acid (13-HODE), 5-hydroxy-6(E),8(Z),11(Z),14(Z)-eicosatetraenoic acid (5-HETE), 8-hydroxy-5(Z),9(E),11(Z),14(Z)-eicosatetraenoic acid (8-HETE), 11-hydroxy-5(Z),8(Z),12(E),14(Z)-eicosatetraenoic acid (11-HETE), 12(S)-hydroxy-5(Z),8(Z),10(E),14(Z)-eicosatetraenoic-5,6,8,9,11,12,14,15-d8 acid (12-HETE-d8), 9-hydroxy-5(Z),7(E),11(Z),14(Z)-eicosatetraenoic acid (9-HETE), 15-hydroxy-5(Z),8(Z),11(Z),13(E)-eicosatetraenoic acid (15-HETE), 12-hydroxy-5(Z),8(Z),10(E),14(Z)-eicosatetraenoic acid (12-HETE) and LTB4 standards were purchased from Cayman Chemicals (Ann Arbor, MI). HPLC-grade acetonitrile, ethanol, methanol, hexane, and hydrochloric acid were from Fisher Chemicals (Loughborough, UK), HPLC-grade acetic acid and methyl formate from Sigma (Dorset, UK), and solid-phase extraction (SPE) cartridges (C18-E, 500 mg, 6 mL) from Phenomenex (Macclesfield, UK).
2.2.2. Solid phase extraction.
Extraction of lipid mediators was carried out according to a previously described method . In summary, mucosal biopsy samples (approximately 3–5 mg) were weighed on thawing and immediately transferred to 15% ice-cold methanol in water (3 mL) and homogenised using Wheaton Tapered tissue grinders. Internal standards (PGE2-d4 and 12-HETE-d8 (20 ng)) were added to each sample. The samples were acidified with 0.05 M hydrochloric acid to pH 3.0 and immediately applied to SPE cartridges that had been preconditioned with 20 mL of methanol, followed by 20 mL of water. The cartridges were then washed with 20 mL of 15% (v/v) methanol, 20 mL of water, and 10 mL of hexane. Finally, the lipid mediators were eluted with 10 mL of methyl formate. The organic solvent was evaporated using a fine stream of nitrogen, the solute reconstituted in ethanol (100 µL), and the final solution stored at −20°C until analysis within 48 hours.
2.2.3. Lipidomics analysis.
Data-dependent LC-MS/MS lipidomics analysis was performed using Accela UHPLC system (Thermo Scientific, Hemel Hempstead, UK) coupled to LTQ Velos (Thermo, Hemel Hempstead, UK) linear ion trap (LIT)-orbitrap as described previously . The analysis on the orbitrap instrument was carried out using heated electrospray ionization (h-ESI) in negative ion mode at sheath, auxiliary and sweep gas flows of 24, 2 and 1, respectively . The capillary and source heater temperatures were set to 275°C and 50°C, respectively. The ion spray voltage was adjusted to 4000 V. MS/MS spectra, along with retention times and isotope distribution patterns from the MS spectra were used to identify lipid mediators in mucosal biopsy samples. The identified metabolites were quantified using Acquity UPLC (Waters, Hertsfordshire, UK) systems coupled to QTRAP 4000 (AB Sciex, Concord, ON) quadrupole−linear ion trap (QqLIT) mass spectrometers as described previously . The lipid mediators were separated on a C18 reversed-phase (RP) LC column (Phenomenex Luna, 3 µm particles, 150×2 mm) using a linear mobile phase gradient (A, 0.02% glacial acetic acid in water; B, 0.02% glacial acetic acid in acetonitrile) at 0.5 mL/min. The starting conditions consisted of 30% B and then increased to 90% B over 14 min and finally returned to the initial conditions for 2 min to allow equilibration.
2.3. Histological Analysis
Assessment was by a histopathologist blinded to patients’ identities and clinical data on paraffin embedded serial haematoxylin and eosin (H&E) stained sections using a validated histopathological scoring tool  (0, normal; 1, mild oedema and inflammation in lamina propria; 2, crypt abscess formation and inflammation in lamina propria; 3, more severe inflammation with destructive crypt abscesses +/−granulomata; 4, more severe inflammation with active ulceration) (Figure 1).
1A: Gomes 0 (normal); 1B: Gomes 1 (mild oedema and inflammation in lamina propria with cryptitis); 1C: Gomes 2 (crypt abscess formation and inflammation); 1D: Gomes 3 (destructive crypt abscesses +/− granulomata); 1E–F: Gomes 4 (active ulceration and formation of granulation tissue with neoangiogenesis).
2.4. Statistical Analysis
Lipid mediator concentration is expressed as pg/mg tissue. Unblinded bioinformatics analysis was carried out following completion of lipid mediator measurement on blinded samples.
2.4.1. Univariate statistical analysis.
Wilcoxon’s Signed Rank Test was used as a non-parametric pair-wise univariate testing method at a confidence interval of 97.5%. Analysis was carried out using custom workflows written in the programming language R. Metabolites with a value of p<0.05 were regarded as significantly different. Subgroup analysis to investigate the effect of no 5-ASA or corticosteroid (n18) use was undertaken and metabolites with a value of p<0.05 were regarded as significantly different.
2.4.2. Multivariate statistical analysis.
Since univariate statistical testing is unable to characterise the interrelationship of variables, multivariate statistical analysis was performed to examine association with disease state (inflamed/non-inflamed) as well as disease severity assessed histologically using the Gomes scoring system. Similar to the paired univariate testing, we were primarily interested in the within-subject variation and therefore performed a variation split prior to analysis (to remove between subject variation), a technique developed in the context of multi-level multivariate data analysis , .
On the remaining within-subject variation data we performed Principal Component Analysis (PCA) for unsupervised analysis, followed by (Orthogonal) Partial Least Squares (PLS) Analysis for the association with disease severity assessed histologically, and (Orthogonal) Partial Least Squares Discriminant Analysis (PLS-DA) for the investigation of the disease state (inflamed/non-inflamed). Variation splitting was implemented using the programming language R, Partial Least Squares Approaches were performed using R as well as SIMCA-P 12.01 (Umetrics, AB, Sweden).
Patients with active UC (n 69) were recruited; biopsy data sets of ‘paired’ macroscopically inflamed and non-inflamed tissues were available in 54 UC patients. Baseline characteristics of patients are shown in Table 1.
3.2. Lipid Mediators: Univariate Analysis
Mucosal biopsies from inflamed and non-inflamed mucosa were screened for all PUFA-derived bioactive lipids and deactivated metabolites. Reported metabolites included eicosanoids derived from AA (TXB2, 6-keto-PGF1α, PGE2, PGD2, 5-HETE, 15-HETE, 12-HETE and 11-HETE) and linoleic acid (LA) (13-HODE, 13-oxo-ODE, 9-HODE). EPA-derived eicosanoids (5-hydroxy-eicosapentaenoic acid (HEPE), 12-HEPE, 15-HEPE) were excluded from analysis as their concentration was below the limit of quantification. Neither PGE3 nor LTB5 were detected.
3.2.1. LOX-related lipid mediators.
5-HETE (p<0.001) and 15-HETE (p<0.001) concentrations in inflamed mucosa were significantly higher than in adjacent non-inflamed mucosa (Table 2, Figure 2). Other 5-LOX metabolites of AA such as LTB4 and 5-oxo-ETE were inconsistently detected. There were no significant differences in the concentrations of LA-derived LOX metabolites such as 9-HODE, 13-HODE and 13-oxo-ODE.
2A: 11-HETE; 2B: 12-HETE; 2C: 15-HETE; 2D: 5-HETE.
3.2.2. COX-related lipid mediators.
PGE2 (p<10−6), PGD2 (p<0.01) and TXB2 (p<10−6) concentrations in inflamed mucosa were significantly higher than in adjacent non-inflamed mucosa (Table 2; Figure 3). There were no other significant differences in concentration of COX metabolites between non-inflamed and inflamed mucosa. PGF2α and the deactivated form of PGE2, 13,14-dihydro-15-keto-PGE2, were only detectable in 50% of the samples and therefore were excluded from analysis.
3.3. Lipid Mediators: Multivariate Analysis
The principal component analysis (PCA), an unsupervised multivariate analysis technique, which is driven by the variance inherent in the data set and has no prior assumption of class membership, revealed a clear differentiation between inflamed and endoscopically non-inflamed adjacent mucosal tissue in patients with distal UC (Figure 4A).
4A: PCA score plot (unsupervised analysis); 4B: O2PLS-DA plot (supervised analysis).
Furthermore, O2-PLSDA, a supervised analysis, was performed to actively check for differences in the lipid mediator profile between inflamed and non-inflamed tissue. As expected from the PCA analysis, the O2PLS-DA model (R2X(cum) = 79%, R2Y(cum) = 60% and Q2 = 60%) was clearly able to differentiate the two phenotypic groups (Figure 4B). Using the O2PLS-DA model, 87.5% of inflamed tissue was correctly identified as inflamed based upon the lipid mediator profile, while 87.5% of non-inflamed tissue was correctly identified as non-inflamed.
In order to investigate which metabolites made the greatest contribution to the separation observed in O2PLS-DA model (Figure 4B), a variable importance plot was created; PGE2 had the highest contribution followed by TXB2, 15-HETE, 5-HETE, 12-HETE and 11-HETE, respectively in diminishing magnitude (Figure 5). This is consistent with the results of the univariate statistical analysis (Table 2), and demonstrates contribution of 12-HETE and 11-HETE which were significantly higher (all p<0.05) in inflamed compared with non-inflamed colonic mucosa in the univariate analysis. PGD2 was excluded from this multivariate analysis as it was detected in <85% of samples.
3.4. Association between Lipid Mediators and Clinical Grading
O2-PLS Analysis was performed in order to examine the relationship between lipid mediator concentration and histological grading (Figure 6). The model (R2X(cum) = 86%, R2Y(cum) = 57% and Q2 = 51%) was able to separate non-inflamed from inflamed tissue; however within the inflamed tissue there was an overlap between histological grades (Figure 6A). Although it was possible to predict mild-moderate inflammation (grade 1 and 2) from the lipid mediator profile (Figure 6B), highly inflamed tissue (grade 3), failed to fit into this model; however this latter group contained 5 subjects only.
6A: Plot showing O2PLS regression score plots; 6B: plot showing actual vs. predicted GOMES score based on lipid mediator profile.
In order to investigate which metabolites had the greatest contribution to the separation observed in the O2PLS model, a variable importance plot was created; PGE2 showed the highest impact followed by 5-HETE, 15-HETE, TXB2, 12-HETE and 11-HETE, respectively in diminishing magnitude (Figure 7).
3.5. 5-ASA and Corticosteroid Naive Patients
Subgroup analysis within ‘paired’ inflamed and non-inflamed mucosa from 18 UC patients (age 45.3 years; male n 10 [55%], female n 8 [45%]) not recently (within 3 months) on 5-ASA or corticosteroid treatment was carried out. Analysis of lipid mediators demonstrated that PGE2, PGD2, TXB2 and 15-HETE (all p<0.05) were higher in inflamed than non-inflamed mucosa; however, the other measured lipid mediators were not significantly different (Table 3). The results within the subgroup analysis are comparable to the total group univariate analysis.
Lipid mediator levels (TXB2 – 38.8 [27.5–51.6]; 6-keto-PGF1α – 36.1 [27.8–49.5]; PGE2 – 14.9 [7.1–24.1]; PGD2 – 9.9 [4.0–17.7]; 9-HODE – 38.3 [20.0–55.6]; 5-HETE – 6.2 [3.0–12.4]; 15-HETE – 19.1 [10.7–32.4]; 13-oxo-ODE – 21.6 [14.8–41.3]; 13-HODE – 55.4 [29.8–84.2]; 12-HETE – 9.1 [5.5–16.5]; 11-HETE – 9.4 [7.0–15.7]) were measured in normal colorectal mucosa obtained from a group of 42 control patients undergoing routine flexible sigmoidoscopy examination.
In the current study we demonstrate differences in the concentration of a number of lipid mediators between inflamed and non-inflamed areas of the colonic mucosa from patients with UC. The findings suggest that inflammation of the colonic mucosa in UC is associated with significant elevation in concentrations of PGE2, PGD2, TXB2, 5-HETE, 15-HETE, 12-HETE and 11-HETE, but not of other measured lipid mediators (Table 2). In addition, the profile of these same lipid mediators correlates with severity of inflammation measured histologically. To our knowledge this is the first study to simultaneously demonstrate comprehensive alterations in multiple lipid mediators, which correlate proportionately to the degree of histological inflammation in patients with UC. This is also in agreement with previous studies that showed upregulation in eicosanoids, which correlate proportionately to the degree of histological inflammation in patients with UC; however, previous studies have been limited to investigation of selected enzymatic pathways (COX-2 and 5-LOX) in UC–, –.
Several of the identified inflammatory mediators have immunomodulatory roles as demonstrated either in cohorts of inflammatory bowel disease (IBD) patients or in experimental studies. For example, PGE2 is produced via COX-1 and COX-2 within the AA cascade and has pro-inflammatory (via cytokine induction pathways) and anti-inflammatory (via lipoxin induction) effects , . PGE2 has been consistently demonstrated in previous studies to be elevated in inflamed colonic mucosa in UC . 12-HETE is produced via 12-LOX within the AA cascade and is known to exert chemotactic effects on neutrophils , . 5-HETE and LTB4 are both products of 5-LOX within the AA cascade; neutrophils contain large quantities of 5-LOX and are able to produce abundant 5-HETE and LTB4 , . 5-HETE is a potent activator of eosinophils and neutrophils via 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE). 5-HETE and 12-HETE were readily detected in inflamed mucosal samples.
LTB4 is a potent chemoattractant for neutrophils and other leukcoytes ; however, LTB4 was not consistently demonstrated in our samples. LTB4 is reported to be elevated in inflamed mucosa in UC; however, critical review of published methods reveals that levels were measured in in vivo rectal dialysates or mucosal explants, which would have led to neutrophil activation inadvertently or by design –. The presented method controls for altered lipid mediator production induced by experimental methods. The lack of consistent demonstration of LTB4 in the context of elevated 5-HETE (both 5-HPETE derivatives) may suggest that the bioactive concentration of LTB4 is below the detectable limit, or that it is rapidly metabolised in inflamed mucosal samples. An alternative explanation, that 5-HETE is the predominant 5-LOX derived chemoattractant lipid mediator, or that PGE2 mediated inhibition of FLAP (5-lipoxygenase activating protein) abrogates LTB4 production, should be considered ; however, this was not specifically tested in our study.
The pro-inflammatory mediator TXB2, a stable derivative of TXA2 and both AA derivatives via COX-dependent conversion from PGH2, is elevated in inflamed compared with non-inflamed mucosa, as has been demonstrated previously .
In contrast, PGD2 and its metabolite 15-deoxy Δ12,14 PGJ2 exert anti-inflammatory effects , and several studies have suggested a role for PGD2 in resolution of inflammation, reduction of leukocyte infiltration and healing within the colon, –. Consistent with other studies, we observed a significant increase in the levels of PGD2 in inflamed tissue, although its metabolite 15-deoxy Δ12,14 PGJ2 was not detectable in mucosal biopsies.
Sub-group analysis (n 18) of a group of patients not receiving corticosteroids and 5-ASA confirmed significant differences in PGE2, PGD2, TXB2 and 15-HETE in inflamed mucosa (Table 3), with no significant differences observed in 5-HETE, 11-HETE and 12-HETE concentrations in inflamed compared with non-inflamed mucosa. This may indicate the diminished power to detect differences in all measured eicosanoids in this group due to sample size, or possibly a more benign clinical course in this untreated group.
Using predictive mathematical modelling, we have demonstrated that the measured lipid mediator profile may be used to predict presence or absence of histological inflammation with sensitivity, specificity, and positive predictive and negative predictive values of 87.5%. It was also possible to grade severity of inflammation based on blinded histological assessment; however, predictive modelling was less consistent in patients with severe inflammation. This may be due to the small group of patients (n 5) in this group, or may suggest that alternative inflammatory mediators become predominant in severe mucosal inflammation.
Eicosanoids and other lipid mediators are generated via oxidative pathways (COX and LOX) at the cytosolic interface of the cell membrane. They have pleiotropic effects and biochemical activity is influenced by the species of PUFA from which they are derived. In excess of 40 different eicosanoids from PUFA substrates are recognised. These are derived from obligate dietary constituents, LA, AA and EPA, but principally from AA due to the higher membrane content of AA and the lower bioavailability of EPA. Provision of EPA orally can influence the levels of AA in cell membranes and reduce pro-inflammatory AA derived lipid mediators in patients with IBD  and in healthy subjects ; although clinical therapeutic efficacy is inconsistently demonstrated , .
In the current study, although AA-derived lipid mediators (PGE2, PGD2, TXB2, 5-HETE, 15-HETE, 12-HETE and 11-HETE) were detectable in inflamed mucosa, EPA-derived mediators (PGE3, PGD3, TXB3, 5-HEPE, 15-HEPE, 12-HEPE and 11-HEPE) were not, or were detected at unquantifiable levels. We previously reported that actively inflamed mucosa in UC is associated with increased AA and reduced EPA in both the complex lipid and free fatty acid pools, with a consistently altered AA/EPA ratio compared with adjacent non-inflamed mucosa, and that this alteration is despite no significant difference in the level of dietary intake of PUFA (Pearl et al) . These findings are consistent and suggest that metabolic alteration of AA production in inflamed tissue may lead to enhanced substrate availability for eicosanoid biosynthetic enzymes which are constitutively up regulated in actively inflamed mucosa, with resulting up regulation in all classes of eicosanoids, which we have detected.
These findings may be relevant to the failure of dietary intervention studies with EPA. This may be because EPA and its lipid mediators including eicosanoids are present at very low levels in inflamed mucosa, whereas AA and its lipid mediators including eicosanoids are present at much higher levels. Supplementation with EPA may not bring about significant rebalancing of the AA/EPA ratio, which would be required to reduce the levels of AA derived eicosanoid lipid mediators in inflamed mucosa.
In addition, eicosanoids derived from both COX- and LOX-related pathways are significantly elevated indicating co-activation of multiple eicosanoid biosynthetic pathways within the AA cascade in inflamed mucosa. The role of eicosanoids is further supported by the known therapeutic effect of 5-ASA drugs, which act by binding to peroxisome proliferator activated receptor γ in the colonic epithelium with subsequent suppression of pro-inflammatory lipid mediator production .
Co-activation of multiple synthetic pathways may suggest redundancy within eicosanoid signalling networks; however, an alternative explanation is that candidate eicosanoid-receptor signalling independently stimulates initiation, propagation, resolution and/or suppression stages of inflammation. This is supported by the observed loss of intestinal eicosanoid homeostasis, as occurs with COX inhibition during non-steroidal anti-inflammatory drug use, which is associated with an increased risk of UC relapse in quiescent disease . This is also supported by detection of pro-inflammatory (PGE2) and anti-inflammatory (PGD2) lipid mediators within the same tissue matrix, as in the current study .
The role of detected eicosanoids (PGE2, PGD2, TXB2, 5-HETE, 15-HETE, 12-HETE and 11-HETE) in UC is difficult to address precisely, as this study was not designed to investigate changes occurring as a result of therapy, or temporal changes in mucosal lipid mediators associated with disease activity.
There is therefore emergent evidence that UC is associated with changes in PUFA profile with elevated AA/EPA ratio suggesting alteration of production of the eicosanoid substrate AA (Pearl et al) , and with associated elevation of AA-derived eicosanoids which correlate with grade of histological inflammation.
Further research should focus on the use of predictive modelling based on mucosal derived lipid mediators to determine if drug non-responders can be predicted, and to target appropriate therapy. This would be a unique development in management of chronic inflammatory disorders.
Additional research could focus on characterization of lipid mediators biosynthesis during initiation, propagation, resolution and suppression stages of inflammation, and to relate these to metabolic activity within the fatty acid biosynthetic cascade. This would allow a focussed time-course assessment of the role of lipid mediators during the evolution of inflammation using distal UC as a model and may inform new targets for development of therapeutic interventions in UC and inflammatory disorders.
In conclusion, development of new approaches and treatments, based on selective lipid mediators, may offer new investigative and therapeutic strategies to target treatment in patients with mild-moderate chronic active steroid and immunomodulator resistant UC in whom an organ sacrificing approach via surgical colectomy is being considered.
Professor Anoop Chauhan (Director of Research, Portsmouth Hospitals NHS Trust (PHT)), for formal approval of IBD biomedical sciences research project, support and mentorship.
Surgeon Commander Mark Whittaker (Consultant Histopathologist, PHT) for unwavering enthusiasm.
Endoscopy staff and patients at PHT
Conceived and designed the experiments: MM DSP TMT JFB JKS. Performed the experiments: MM DSP. Analyzed the data: MM ME DSP TMT PCC. Contributed reagents/materials/analysis tools: DSP MM ME TMT. Wrote the paper: MM DSP ME. Critical revision of the manuscript for important intellectual content: DSP MM ME JFB JKS PCC TMT. Obtained funding: DSP MM JFB JKS TMT. Study supervision JFB JKS PCC TMT. Acquisition of data: MM DSP TMT. Statistical analysis: ME MM DSP. Technical or material support: DSP MM ME TMT.
- 1. 1. Stonnington CM, Phillips SF, Melton LJ III, Zinsmeister AR (1987) Chronic ulcerative colitis: incidence and prevalence in a community. Gut 28: 402–409.
- 2. Pearl DS, Shah K, Whittaker MA, Nitch-Smith H, Brown JF, et al.. (2012) Cytokine mucosal expression in ulcerative colitis, the relationship between cytokine release and disease activity. J Crohns Colitis. S1873-9946(12)00333-9 [pii];10.1016/j.crohns.2012.07.022 [doi].
- 3. Lawson MM, Thomas AG, Akobeng AK (2006) Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev CD005112. 10.1002/14651858.CD005112.pub2 [doi].
- 4. Peyrin-Biroulet L, Lemann M (2011) Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 33: 870–879 10.1111/j.1365-2036.2011.04599.x [doi].
- 5. Jakobovits SL, Travis SP (2005) Management of acute severe colitis. Br Med Bull 75–76: 131–144 75-76/1/131 [pii];10.1093/bmb/ldl001 [doi].
- 6. Langholz E, Munkholm P, Davidsen M, Binder V (1994) Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107: 3–11. S0016508594002155 [pii].
- 7. Langholz E (2010) Current trends in inflammatory bowel disease: the natural history. Therap Adv Gastroenterol 3: 77–86 10.1177/1756283X10361304 [doi].
- 8. Geboes JK (2003) Histopathology of Crohn’s disease and ulcerative colitis. In: Satsangi J, Sutherland LR, Colombel JF, Fiocci C, Lofberg R et al.., editors. Inflammatory Bowel Disease. Edinburgh, London, Melbourne: Churchill Livingstone. 255–276.
- 9. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, et al. (2000) A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47: 404–409.
- 10. Azad S, Sood N, Sood A (2011) Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. Saudi J Gastroenterol 17: 194–198 SaudiJGastroenterol_2011_17_3_194_80383 [pii];10.4103/1319-3767.80383 [doi].
- 11. Nielsen OH, Elmgreen J (1987) Activation of neutrophil chemotaxis by leukotriene B4 and 5-hydroxyeicosatetraenoic acid in chronic inflammatory bowel disease. Scand J Clin Lab Invest 47: 605–611.
- 12. Palmblad J (1984) The role of granulocytes in inflammation. Scand J Rheumatol 13: 163–172.
- 13. Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, et al. (2005) Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54: 960–965 54/7/960 [pii];10.1136/gut.2004.060103 [doi].
- 14. Sutherland L, Roth D, Beck P, May G, Makiyama K (2000) Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. Cochrane Database Syst Rev CD000543. CD000543 [pii];10.1002/14651858.CD000543 [doi].
- 15. Funk CD (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871–1875 10.1126/science.294.5548.1871 [doi];294/5548/1871 [pii].
- 16. Jupp J, Hillier K, Elliott DH, Fine DR, Bateman AC, et al. (2007) Colonic expression of leukotriene-pathway enzymes in inflammatory bowel diseases. Inflamm Bowel Dis 13: 537–546 10.1002/ibd.20094 [doi].
- 17. Rampton DS, Sladen GE, Youlten LJ (1980) Rectal mucosal prostaglandin E2 release and its relation to disease activity, electrical potential difference, and treatment in ulcerative colitis. Gut 21: 591–596.
- 18. Sharon P, Stenson WF (1984) Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 86: 453–460. S0016508584000500 [pii].
- 19. Lee TH, Sethi T, Crea AE, Peters W, Arm JP, et al. (1988) Characterization of leukotriene B3: comparison of its biological activities with leukotriene B4 and leukotriene B5 in complement receptor enhancement, lysozyme release and chemotaxis of human neutrophils. Clin Sci (Lond) 74: 467–475.
- 20. Needleman P, Raz A, Minkes MS, Ferrendelli JA, Sprecher H (1979) Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci U S A 76: 944–948.
- 21. Turner D, Steinhart AH, Griffiths AM (2007) Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev CD006443. 10.1002/14651858.CD006443.pub2 [doi].
- 22. Calder PC (2008) Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 52: 885–897 10.1002/mnfr.200700289 [doi].
- 23. D’Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, et al. (2011) The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 106: 199–212 ajg2010392 [pii];10.1038/ajg.2010.392 [doi].
- 24. Gomes P, du BC, Smith CL, Holdstock G (1986) Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 27: 92–95.
- 25. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, et al.. (1987) 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92: 1894–1898. S0016508587001811 [pii].
- 26. Masoodi M, Eiden M, Koulman A, Spaner D, Volmer DA (2010) Comprehensive lipidomics analysis of bioactive lipids in complex regulatory networks. Anal Chem 82: 8176–8185 10.1021/ac1015563 [doi].
- 27. Jansen JJ, Hoefsloot HC, van der Greef J, Timmerman ME, Westerhuis JA, et al. (2006) ASCA: analysis of multivariate data obtained from an experimental design. J Chemometrics 19: 469–481.
- 28. van Velzen EJ, Westerhuis JA, van Duynhoven JP, van Dorsten FA, Hoefsloot HC, et al. (2008) Multilevel data analysis of a crossover designed human nutritional intervention study. J Proteome Res 7: 4483–4491 10.1021/pr800145j [doi].
- 29. Boughton-Smith NK, Hawkey CJ, Whittle BJ (1983) Biosynthesis of lipoxygenase and cyclo-oxygenase products from [14C]-arachidonic acid by human colonic mucosa. Gut 24: 1176–1182.
- 30. Gould SR (1976) Assay of prostaglandin-like substances in faeces and their measurement in ulcerative colitis. Prostaglandins 11: 489–497.
- 31. Rampton DS, Sladen GE, Youlten LJ (1980) Prostaglandins and ulcerative colitis. Gastroenterology 78: 192–193.
- 32. Vong L, Ferraz JG, Panaccione R, Beck PL, Wallace JL (2010) A pro-resolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis. Proc Natl Acad Sci U S A 107: 12023–12027 1004982107 [pii];10.1073/pnas.1004982107 [doi].
- 33. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2: 612–619 10.1038/89759 [doi];89759 [pii].
- 34. Vachier I, Chanez P, Bonnans C, Godard P, Bousquet J, et al. (2002) Endogenous anti-inflammatory mediators from arachidonate in human neutrophils. Biochem Biophys Res Commun 290: 219–224 10.1006/bbrc.2001.6155 [doi];S0006291X01961558 [pii].
- 35. Palmer RM, Stepney RJ, Higgs GA, Eakins KE (1980) Chemokinetic activity of arachidonic and lipoxygenase products on leuocyctes of different species. Prostaglandins 20: 411–418.
- 36. Turner SR, Tainer JA, Lynn WS (1975) Biogenesis of chemotactic molecules by the arachidonate lipoxygenase system of platelets. Nature 257: 680–681.
- 37. Borgeat P, Samuelsson B (1979) Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids. Proc Natl Acad Sci U S A 76: 3213–3217.
- 38. Borgeat P, Samuelsson B (1979) Metabolism of arachidonic acid in polymorphonuclear leukocytes. Structural analysis of novel hydroxylated compounds. J Biol Chem 254: 7865–7869.
- 39. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJ (1980) Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286: 264–265.
- 40. Shimizu T, Fujii T, Suzuki R, Igarashi J, Ohtsuka Y, et al. (2003) Effects of highly purified eicosapentaenoic acid on erythrocyte fatty acid composition and leukocyte and colonic mucosa leukotriene B4 production in children with ulcerative colitis. J Pediatr Gastroenterol Nutr 37: 581–585.
- 41. Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K (1992) 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents Actions Spec No: C37–C46.
- 42. Pearl DS, Masoodi M, Eiden M, Brummer J, Gullick D, et al.. (2013) Altered colonic mucosal availability of n-3 and n-6 polyunsaturated fatty acids in ulcerative colitis and the relationship to disease activity. J Crohns Colitis. S1873-9946(13)00137-2 [pii];10.1016/j.crohns.2013.03.013 [doi].
- 43. Lobos EA, Sharon P, Stenson WF (1987) Chemotactic activity in inflammatory bowel disease. Role of leukotriene B4. Dig Dis Sci 32: 1380–1388.
- 44. Ikehata A, Hiwatashi N, Kinouchi Y, Yamazaki H, Ito K, et al. (1995) Altered leukotriene B4 metabolism in colonic mucosa with inflammatory bowel disease. Scand J Gastroenterol 30: 44–49.
- 45. Gertner DJ, Rampton DS, Madden MV, Talbot IC, Nicholls RJ, et al. (1994) Increased leukotriene B4 release from ileal pouch mucosa in ulcerative colitis compared with familial adenomatous polyposis. Gut 35: 1429–1432.
- 46. Eliakim R, Karmeli F, Chorev M, Okon E, Rachmilewitz D (1992) Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis. Scand J Gastroenterol 27: 968–972.
- 47. Cole AT, Pilkington BJ, McLaughlan J, Smith C, Balsitis M, et al. (1996) Mucosal factors inducing neutrophil movement in ulcerative colitis: the role of interleukin 8 and leukotriene B4. Gut 39: 248–254.
- 48. Casellas F, Papo M, Guarner F, Antolin M, Segura RM, et al. (1995) Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis. Eur J Gastroenterol Hepatol 7: 221–226.
- 49. Harizi H, Juzan M, Moreau JF, Gualde N (2003) Prostaglandins inhibit 5-lipoxygenase-activating protein expression and leukotriene B4 production from dendritic cells via an IL-10-dependent mechanism. J Immunol 170: 139–146.
- 50. Carty E, De BM, Feakins RM, Rampton DS (2000) Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut 46: 487–492.
- 51. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, et al. (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5: 698–701 10.1038/9550 [doi].
- 52. Ajuebor MN, Singh A, Wallace JL (2000) Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. Am J Physiol Gastrointest Liver Physiol 279: G238–G244.
- 53. Rajakariar R, Hilliard M, Lawrence T, Trivedi S, Colville-Nash P, et al. (2007) Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci U S A 104: 20979–20984 0707394104 [pii];10.1073/pnas.0707394104 [doi].
- 54. Zamuner SR, Warrier N, Buret AG, MacNaughton WK, Wallace JL (2003) Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. Gut 52: 1714–1720.
- 55. Trebble TM, Arden NK, Wootton SA, Calder PC, Mullee MA, et al.. (2004) Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease. Am J Clin Nutr 80: 1137–1144. 80/5/1137 [pii].
- 56. Trebble TM, Wootton SA, Miles EA, Mullee M, Arden NK, et al. (2003) Prostaglandin E2 production and T cell function after fish-oil supplementation: response to antioxidant cosupplementation. Am J Clin Nutr 78: 376–382.
- 57. Hawthorne AB, Daneshmend TK, Hawkey CJ, Belluzzi A, Everitt SJ, et al. (1992) Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 33: 922–928.
- 58. Ananthakrishnan AN, Higuchi LM, Huang ES, Khalili H, Richter JM, et al. (2012) Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med 156: 350–359 156/5/350 [pii];10.1059/0003-4819-156-5-201203060-00007 [doi].
- 59. D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, et al. (2007) A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132: 763–786 S0016-5085(06)02688-6 [pii];10.1053/j.gastro.2006.12.038 [doi].